SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Enfusion, Inc. – ENFN

NEW YORK, March 19, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Enfusion, Inc. (“Enfusion” or the “Company”) (NYSE: ENFN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

The investigation concerns whether Enfusion and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action] 

On March 14, 2024, Spruce Point Capital (“Spruce Point”) published a short report alleging that “a financial restatement risk is high and that the company is likely to disappoint investor expectations.” Among other items, the report asserted that while “Enfusion claims to be a high-growth SaaS provider of financial software with multi-year contracts, . . . we don’t believe it to be a high quality one”; that “[t]he company has experienced significant executive turnover including the CEO, CFO, Chief Revenue Officer (CRO), and Chief Strategy Officer (CSO) roles”; and that “[w]e believe revenue is at high risk of misstatement as we find accounts that appear to have been quietly revised or do not reconcile”. On this news, Enfusion’s stock price fell sharply on March 14, 2024.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-enfusion-inc—enfn-302093534.html

SOURCE Pomerantz LLP